Pasireotide and Ofloxacin Otic: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Ofloxacin Otic
Pasireotide
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased risk of QT prolongation
Interaction Deep Dive
Pasireotide is associated with QT-interval prolongation. In 2 studies, QT prolongation occurred at both therapeutic and supratherapeutic doses of pasireotide. Concomitant administration of pasireotide with other drugs that prolong the QT interval, including antiarrhythmic medications, may have additive prolonging effects on the QT interval. ECGs at baseline and at 21 days after treatment initiation are recommended when pasireotide is coadministered with other QT-prolonging agents1.
Why it happens (mechanism)
Additive QT-interval prolongation
Common questions
Can I take Pasireotide and Ofloxacin Otic together?
Increased risk of QT prolongation Always confirm with your pharmacist or prescriber before making any change.
How serious is the Pasireotide and Ofloxacin Otic interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Pasireotide or Ofloxacin Otic need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: SIGNIFOR(R) LAR intramuscular injection suspension, pasireotide intramuscular injection suspension. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2014.
Keep reading about Ofloxacin Otic
Keep reading about Pasireotide
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist